Bruce Booth Sells 1,408 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Bruce Booth sold 1,408 shares of the stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $99.98, for a total transaction of $140,771.84. Following the completion of the transaction, the director directly owned 613,589 shares of the company’s stock, valued at approximately $61,346,628.22. The trade was a 0.23% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bruce Booth also recently made the following trade(s):

• On Thursday, June 25th, Bruce Booth sold 285,684 shares of Kymera Therapeutics stock. The stock was sold at an average price of $121.86, for a total transaction of $34,813,452.24.
• On Thursday, June 25th, Bruce Booth sold 262,637 shares of Kymera Therapeutics stock. The shares were sold at an average price of $115.39, for a total value of $30,305,683.43.
• On Wednesday, June 24th, Bruce Booth sold 134,720 shares of Kymera Therapeutics stock. The shares were sold at an average price of $100.51, for a total value of $13,540,707.20.
• On Monday, June 22nd, Bruce Booth sold 246,330 shares of Kymera Therapeutics stock. The stock was sold at an average price of $98.52, for a total value of $24,268,431.60.
• On Thursday, June 18th, Bruce Booth sold 115,056 shares of Kymera Therapeutics stock. The stock was sold at an average price of $91.01, for a total value of $10,471,246.56.
• On Wednesday, June 17th, Bruce Booth sold 105,071 shares of Kymera Therapeutics stock. The shares were sold at an average price of $90.38, for a total value of $9,496,316.98.
• On Wednesday, June 17th, Bruce Booth sold 11,741 shares of Kymera Therapeutics stock. The shares were sold at an average price of $89.98, for a total value of $1,056,455.18.
• On Monday, June 22nd, Bruce Booth sold 31,798 shares of Kymera Therapeutics stock. The shares were sold at an average price of $103.75, for a total value of $3,299,042.50.
• On Wednesday, April 22nd, Bruce Booth sold 100 shares of Kymera Therapeutics stock. The stock was sold at an average price of $90.08, for a total value of $9,008.00.
• On Wednesday, April 22nd, Bruce Booth sold 5,900 shares of Kymera Therapeutics stock. The shares were sold at an average price of $89.96, for a total value of $530,764.00.

Kymera Therapeutics Price Performance

Shares of NASDAQ KYMR opened at $108.12 on Friday. The company has a 50 day simple moving average of $84.81 and a 200 day simple moving average of $82.31. Kymera Therapeutics, Inc. has a 1 year low of $36.65 and a 1 year high of $130.05. The firm has a market cap of $8.89 billion, a PE ratio of -30.29 and a beta of 2.02.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.18. The firm had revenue of $34.37 million for the quarter, compared to analyst estimates of $8.27 million. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The company’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.82) EPS. As a group, research analysts anticipate that Kymera Therapeutics, Inc. will post -3.25 earnings per share for the current fiscal year.

Kymera Therapeutics News Roundup

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Kymera completed enrollment in its Phase 2b BROADEN2 trial for KT-621 ahead of schedule, accelerating the timeline for topline data to year-end 2026 and lifting optimism about the atopic dermatitis program. Article: Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026
• Positive Sentiment: BTIG Research reaffirmed a buy rating on Kymera Therapeutics and set a $134 price target, reinforcing bullish expectations for the stock. Article: Kymera Therapeutics Stock Climbs On Accelerated Timeline For Lead Atopic Dermatitis Program
• Neutral Sentiment: Kymera appointed Felix J. Baker, Ph.D. as chairman of the board, a leadership change that supports oversight but is less likely to move shares on its own. Article: Kymera Therapeutics Appoints Felix J. Baker, Ph.D. as Chairman of the Board of Directors
• Negative Sentiment: Recent insider selling, including shares sold by Noah Goodman and multiple sales by director Bruce Booth, may raise some caution despite being tied to a pre-arranged trading plan. Article: Insider transaction filing

Analysts Set New Price Targets

Several brokerages have commented on KYMR. Wall Street Zen raised Kymera Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 2nd. Morgan Stanley restated an “overweight” rating and set a $119.00 price objective on shares of Kymera Therapeutics in a research report on Thursday, April 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kymera Therapeutics in a research note on Tuesday, April 21st. Loop Capital set a $97.00 target price on Kymera Therapeutics in a report on Monday, June 8th. Finally, Canaccord Genuity Group increased their target price on shares of Kymera Therapeutics from $106.00 to $129.00 and gave the company a “buy” rating in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $118.18.

Institutional Investors Weigh In On Kymera Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Baker BROS. Advisors LP boosted its holdings in shares of Kymera Therapeutics by 30.2% during the 4th quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock worth $673,620,000 after buying an additional 2,005,813 shares in the last quarter. Avoro Capital Advisors LLC lifted its position in shares of Kymera Therapeutics by 17.7% during the 4th quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock valued at $581,610,000 after acquiring an additional 1,124,747 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in Kymera Therapeutics by 20.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock worth $479,258,000 after acquiring an additional 1,061,957 shares in the last quarter. Vanguard Group Inc. boosted its stake in Kymera Therapeutics by 15.6% during the fourth quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock worth $487,685,000 after acquiring an additional 845,922 shares in the last quarter. Finally, Holocene Advisors LP acquired a new stake in Kymera Therapeutics in the third quarter worth $47,563,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.